Simona Sapino

Dr. Simona Sapino

University of Torino, Department of Drug Science and Technology, 10125 Turin, Italy
orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2015 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
Simona SapinoSimona Sapino
Simona Sapino
EUElena Ugazio
Elena Ugazio
LGLucia Gastaldi
Lucia Gastaldi
Ivana MilettoIvana Miletto
Ivana Miletto
Gloria BerlierGloria Berlier
Gloria Berlier
SOSimonetta Oliaro-Bosso
Simonetta Oliaro-Bosso

24 January 2020 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Gamal Eldein Fathy Abd-Ellatef Abd-ElrahmanGamal Eldein Fathy Abd-Ellatef Abd-Elrahman
Gamal Eldein Fathy Abd-Ellatef Abd-Elrahman
Elena GazzanoElena Gazzano
Elena Gazzano
DCDaniela Chirio
Daniela Chirio
AHAhmed Ragab Hamed
Ahmed Ragab Hamed
DBDimas Carolina Belisario
Dimas Carolina Belisario
Chiara RigantiChiara Riganti
Chiara Riganti
Multidrug resistance (MDR) is a critical hindrance to the success of cancer chemotherapy. The main thing responsible for MDR phenotypes are plasma-membranes associated with adenosine triphosphate (ATP) Binding Cassette (ABC) drug efflux transporters, such as the P-glycoprotein (Pgp) transporter that has the broadest spectrum of substrates. Curcumin (CURC) is a Pgp inhibitor, but it is poorly soluble and bioavailable. To overcome these limitations, we validated the efficacy and safety of CURC, loaded in biocompatible solid lipid nanoparticles (SLNs), with or without chitosan coating, with the goal of increasing the stability, homogeneous water dispersibility, and cellular uptake. Both CURC-loaded SLNs were 5–10-fold more effective than free CURC in increasing the intracellular retention and toxicity of doxorubicin in Pgp-expressing triple negative breast cancer (TNBC). The effect was due to the decrease of intracellular reactive oxygen species, consequent inhibition of the Akt/IKKα-β/NF-kB axis, and reduced transcriptional activation of the Pgp promoter by p65/p50 NF-kB. CURC-loaded SLNs also effectively rescued the sensitivity to doxorubicin against drug-resistant TNBC tumors, without signs of systemic toxicity. These results suggest that the combination therapy, based on CURC-loaded SLNs and doxorubicin, is an effective and safe approach to overcome the Pgp-mediated chemoresistance in TNBC.

1 May 2020 in Nanomaterials
Verified
Journal Article
Open access
PDF file
Giulia ChindamoGiulia Chindamo
Giulia Chindamo
Simona SapinoSimona Sapino
Simona Sapino
EPElena Peira
Elena Peira
DCDaniela Chirio
Daniela Chirio
MGMónica Cristina Gonzalez
Mónica Cristina Gonzalez
Marina GallarateMarina Gallarate
Marina Gallarate
Bone diseases include a wide group of skeletal-related disorders that cause mobility limitations and mortality. In some cases, e.g., in osteosarcoma (OS) and metastatic bone cancer, current treatments are not fully effective, mainly due to low patient compliance and to adverse side effects. To overcome these drawbacks, nanotechnology is currently under study as a potential strategy allowing specific drug release kinetics and enhancing bone regeneration. Polymers, ceramics, semiconductors, metals, and self-assembled molecular complexes are some of the most used nanoscale materials, although in most cases their surface properties need to be tuned by chemical or physical reactions. Among all, scaffolds, nanoparticles (NPs), cements, and hydrogels exhibit more advantages than drawbacks when compared to other nanosystems and are therefore the object of several studies. The aim of this review is to provide information about the current therapies of different bone diseases focusing the attention on new discoveries in the field of targeted delivery systems. The authors hope that this paper could help to pursue further directions about bone targeted nanosystems and their application for bone diseases and bone regeneration.

1 September 2016 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
EUElena Ugazio
Elena Ugazio
LGLucia Gastaldi
Lucia Gastaldi
VBValentina Brunella
Valentina Brunella
DSDominique Scalarone
Dominique Scalarone
SJSushilkumar A Jadhav
Sushilkumar A Jadhav
Simona SapinoSimona Sapino
Simona Sapino

1 March 2013 in Journal of Colloid and Interface Science
Verified
Journal Article
Closed access
Gloria BerlierGloria Berlier
Gloria Berlier
LGLucia Gastaldi
Lucia Gastaldi
EUElena Ugazio
Elena Ugazio
Ivana MilettoIvana Miletto
Ivana Miletto
PIPatrizia Iliade
Patrizia Iliade
Simona SapinoSimona Sapino
Simona Sapino

1 November 2013 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
Gloria BerlierGloria Berlier
Gloria Berlier
LGLucia Gastaldi
Lucia Gastaldi
Simona SapinoSimona Sapino
Simona Sapino
Ivana MilettoIvana Miletto
Ivana Miletto
EBEmanuela Bottinelli
Emanuela Bottinelli
EUElena Ugazio
Elena Ugazio